FDA Faces Lawsuit Over NMN Legality — Industry Pushes Back

The lawsuit, filed on August 28, 2024, accuses the FDA of misusing the Federal Food, Drug, and Cosmetic Act to retroactively ban NMN as a dietary ingredient. The NPA argues that FDA’s reversal lacks legal basis, transparency, and consistency — raising broader concerns for the entire nutraceutical industry.

“This is not just about NMN,” said Dr. Daniel Fabricant, CEO of the NPA. “It’s about how the FDA’s actions threaten innovation and consumer access to safe, science-based nutrition.”

NMN and Its Role in Cellular Health

NMN, a form of Vitamin B3 and a key NAD⁺ precursor, plays a vital role in energy metabolism, DNA repair, and liver detoxification. It has repeatedly demonstrated safety and efficacy and was recognized by the FDA in 2022 as a lawful dietary ingredient before being suddenly revoked.

Why This Matters

The outcome of this lawsuit could redefine how regulators handle novel dietary ingredients (NDIs) in the U.S. If the FDA’s current interpretation stands, it could give pharmaceutical interests the ability to exclude safe, evidence-based ingredients from the supplement market — stifling innovation and limiting global consumer choice.

HumanPro’s Perspective

At HumanPro, we believe in a transparent, science-driven approach to nutrition. As an international supplier of advanced nutraceutical and functional ingredients, we support global efforts to protect innovation and ensure that consumers continue to have access to high-quality, research-backed ingredients such as NMN, NAC, and TUDCA.

“Innovation and compliance can — and must — coexist. The future of health nutrition depends on evidence, integrity, and collaboration across the industry.” — HumanPro R&D Team